• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib.

作者信息

Bergantini Laura, Bargagli Elena, Cameli Paolo, Cekorja Behar, Lanzarone Nicola, Pianigiani Lucrezia, Vietri Lucia, Bennett David, Sestini Piersante, Rottoli Paola

机构信息

Department of Clinical Medical and Neurosciences, Respiratory Disease and Lung Transplantation Section, Le Scotte Hospital, University of Siena, Siena, Italy.

Department of Clinical Medical and Neurosciences, Respiratory Disease and Lung Transplantation Section, Le Scotte Hospital, University of Siena, Siena, Italy.

出版信息

Respir Investig. 2019 May;57(3):290-291. doi: 10.1016/j.resinv.2019.02.001. Epub 2019 Feb 21.

DOI:10.1016/j.resinv.2019.02.001
PMID:30799155
Abstract
摘要

相似文献

1
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib.使用尼达尼布治疗的特发性肺纤维化患者的连续KL-6分析
Respir Investig. 2019 May;57(3):290-291. doi: 10.1016/j.resinv.2019.02.001. Epub 2019 Feb 21.
2
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.基线血浆 KL-6 水平可预测接受尼达尼布治疗的特发性肺纤维化患者的不良结局：一项回顾性真实世界队列研究。
BMC Pulm Med. 2021 May 15;21(1):165. doi: 10.1186/s12890-021-01530-6.
3
Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis.特发性肺纤维化患者血清KL-6连续检测的预后价值
Respir Investig. 2017 Jan;55(1):16-23. doi: 10.1016/j.resinv.2016.09.003. Epub 2016 Nov 9.
4
Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.尼达尼布治疗特发性肺纤维化患者后显著改善
Intern Med. 2019 Apr 15;58(8):1141-1144. doi: 10.2169/internalmedicine.1890-18. Epub 2018 Dec 18.
5
The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression.未经治疗的特发性肺纤维化患者血清KL-6水平可随疾病进展而自然下降。
Clin Respir J. 2018 Sep;12(9):2411-2418. doi: 10.1111/crj.12946. Epub 2018 Aug 13.
6
Evaluation and management of Idiopathic Pulmonary Fibrosis.特发性肺纤维化的评估与管理
Respir Investig. 2019 Jul;57(4):300-311. doi: 10.1016/j.resinv.2019.02.003. Epub 2019 Mar 8.
7
Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis.特发性肺纤维化患者血清中胰岛素样生长因子结合蛋白-1和胰岛素样生长因子结合蛋白-2水平升高。
BMC Pulm Med. 2016 May 23;16(1):86. doi: 10.1186/s12890-016-0249-6.
8
Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis.尼达尼布治疗特发性肺纤维化期间患者报告结局及用力肺活量的改善
Tohoku J Exp Med. 2018 Jun;245(2):107-114. doi: 10.1620/tjem.245.107.
9
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.特发性肺纤维化的用力肺活量——美国食品药品监督管理局对吡非尼酮和尼达尼布的审评
N Engl J Med. 2015 Mar 26;372(13):1189-91. doi: 10.1056/NEJMp1500526.
10
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis.基线KL-6可预测特发性肺纤维化急性加重风险增加。
Respir Med. 2014 Jul;108(7):1031-9. doi: 10.1016/j.rmed.2014.04.009. Epub 2014 Apr 26.

引用本文的文献

1
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease.KL6水平的纵向变化可预测纤维化间质性肺疾病的急性加重。
Sci Rep. 2025 Jul 18;15(1):26061. doi: 10.1038/s41598-025-12236-8.
2
Does the IL-6/KL-6 ratio distinguish different phenotypes in COVID-19 Acute Respiratory Distress Syndrome? An observational study stemmed from prospectively derived clinical, biological, and computed tomographic data.IL-6/KL-6比值能否区分新型冠状病毒肺炎急性呼吸窘迫综合征的不同表型？一项基于前瞻性收集的临床、生物学和计算机断层扫描数据的观察性研究。
PLoS One. 2025 May 21;20(5):e0321533. doi: 10.1371/journal.pone.0321533. eCollection 2025.
3
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.
尼达尼布对特发性肺纤维化循环生物标志物的影响。
ERJ Open Res. 2024 Dec 16;10(6). doi: 10.1183/23120541.00558-2023. eCollection 2024 Nov.
4
The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis.成纤维细胞活化蛋白α作为肺纤维化的生物标志物。
Front Med (Lausanne). 2024 Sep 19;11:1393778. doi: 10.3389/fmed.2024.1393778. eCollection 2024.
5
State of the Globe: A Glimmer of Hope - Biomarkers for Diagnosing COVID-19 Pulmonary Fibrosis.全球状况：一线希望——用于诊断新冠肺纤维化的生物标志物
J Glob Infect Dis. 2024 Jun 26;16(2):43-44. doi: 10.4103/jgid.jgid_119_24. eCollection 2024 Apr-Jun.
6
Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone.黏蛋白-1的基线血液水平与接受抗纤维化药物吡非尼酮治疗的特发性肺纤维化患者治疗期间的关键不良结局相关。
Biomedicines. 2024 Feb 8;12(2):402. doi: 10.3390/biomedicines12020402.
7
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.肺腺癌 6 作为 COVID-19 患者疾病严重程度标志物：Tosoh AIA-360 与 Lumipulse G600II 的分析验证和质量评估。
Int J Environ Res Public Health. 2022 Feb 15;19(4):2176. doi: 10.3390/ijerph19042176.
8
Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study.接受抗纤维化治疗的特发性肺纤维化患者循环中KL-6、SP-D、MMP-7、CA19-9、CA-125、CCL18和骨膜蛋白的系列测量：一项探索性研究
J Clin Med. 2021 Aug 28;10(17):3864. doi: 10.3390/jcm10173864.
9
Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.特发性肺纤维化的分子生物标志物：现状与未来方向。
Int J Mol Sci. 2021 Jun 10;22(12):6255. doi: 10.3390/ijms22126255.
10
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.基线血浆 KL-6 水平可预测接受尼达尼布治疗的特发性肺纤维化患者的不良结局：一项回顾性真实世界队列研究。
BMC Pulm Med. 2021 May 15;21(1):165. doi: 10.1186/s12890-021-01530-6.